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Abstract This study is focused on the properties of the
monobloc hydrogel (MH) breast implant, which has been
around for more than 30 years, and to see how it behaves
with regard to health complaints as sometimes seen in some
patients who had received silicone gel (SG) breast implants.
Patients responded to a questionnaire examining their
experience with breast implants. Three groups were
included. First, the control group (n=34) of women without
breast implants. Second, a C group of women (n=42) who
began and remained on the MH implant. Third, the B group
of women who had their silicone gel implant replaced by
the MH implant. In the B1 subgroup (n=22), a capsulec-
tomy was also performed. In the B2 subgroup (n=13), the
replacement was carried out without a capsulectomy. The C
group behaved very much like the control group. The
women of the B group experienced an improvement of their
complaints and the improvement was even better after a
capsulectomy. The only difference between the MH and SG
implants is the content of the implant. The satisfaction of
women with MH implants is generally high and not or
hardly associated with health complaints. In women with
SG implants and health complaints, these complaints can be
relieved by replacement of the implants by MH implants.
Keywords Monobloc hydrogel implant.Silicone breast
implant.Breast augmentation.Breast reconstruction
Introduction
For decades, breast implants have been used to augment or
reconstruct the female breasts. Three types of implants are
available: implants filled with saline, implants filled with
silicone gel (SG) and silicone oil and implants filled with a
mixture of saline and cellulose, called the monobloc
hydrogel (MH). The SG implant is used most frequently,
whereas the saline implants are hardly used anymore. All of
these breast implants have a silicone elastomere shell.
The MH breast implant was developed in the 1970s by
the late Arion [1]. He was a French plastic surgeon who
was also an engineer and he was motivated to create this
implant by the patients who had silicone granulomas [2].
The major property of the MH implant is a biodegradable
content of 97% saline and 3% cellulose (carboxymethyl-
cellulose). The MH implant comes very close to being a
saline implant, and with this, it has in common a chance of
spontaneous rupture. The reason for this is unknown. In
case of a rupture, the hydrogel will cause the production of
clear serous fluid, without the implant becoming empty. As
a result there will be an increase of one cup size within a
couple of days and therefore the patient will be alarmed by
the implant itself that it has ruptured. The replacement can
be planned as an elective procedure under local anaesthesia
of the submammary scar within 20 min, because the
implant is never adherent to the capsule as is usually the
case with a textured SG implant. The serous liquid is
drained and the use of drains is a contraindication. The
MH-augmented or -reconstructed breast looks very natural
(Fig. 1) and feels soft because of the absence of capsular
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cally in patients who had SG implants before they received
the MH implant. The MH implant is reported by patients to
take on body temperature easier than alternative implants,
and radiologists have less difficulty in examining the
mammary gland. It is delivered in many sizes as a round
implant with a high profile and has a CE mark. There is a
chance of visible rippling when the skin and subcutaneous
cover are thin. This can be corrected with lipofilling or the
use of a commercial Tissue Matrix.
There are two indications for using the MH implant. The
first is the choice of women who do not want the SG
implant nor an extensive autologous reconstruction, and the
second, to have another option for women who have
reacted adversely to the SG implant.
In summary, the main characteristics of the MH
implant are the possession of a CE mark, a biodegrad-
able filling, self-alarm and easy replacement under local
anaesthesia in an outpatient procedure in case of a
spontaneous rupture, a natural look and feel, and lack of
capsular contracture. In this article, the performance of
the MH implant is presented separately from that of the
SG implants. The MH implant should not be confused
with the related Poly Implant Prostheses (PIP) implant,
which has a content of hydroxypropyl cellulose hydrogel.
The PIP implant was taken from the market by the
Medical Devices Agency in the UK because there was one
report of a filler leak and the manufacturer's biological safety
assessment of this product was inadequate. Explantation of
the PIP implant was not recommended. The aim of this study
was to investigate the behaviour of the MH implant and to
investigate whether women with MH implants may inciden-
tally experience similar health complaints as those that are
sometimes seen in women with SG implants.
Methods
Women in a general plastic surgery practice who received
the MH implant either as the first implant (C group, n=42)
or had a replacement of the SG implant by the MH implant
because of health complaints (B group, n=35) filled out
questionnaires with regard to complaints that patients with
SG implants in some cases tend to have, such as chronic
fatigue, painful joints and muscles, etc. Participants could
also give their opinion on the aesthetic results. The B group
was subdivided in those who had an additional capsulec-
tomy (B1 group, n=22) and those without capsulectomy
(B2 group, n=13). The same questions were put forward to
the control group (n=34), which was recruited from healthy
female hospital workers without breast implants. The reader
is referred to Table 1 for an overview of the general
characteristics of the groups. When the results for pre- and
post-operative parameters were compared, paired t tests
were used to analyse the statistical significance.
Results
Women with MH breast implants (C group), SG implants
replaced by MH implants (B1 and B2 groups), and a
control group without implants were asked to share their
experiences through filling out questionnaires focused on
health problems and general aspects related to the breast
Fig. 1 Breast augmentation and
reconstruction with monobloc
hydrogel implants. Images of
pre-operative (a) and
post-operative (b) chest of a
woman who had breast
augmentation with the MH
implant. Images of pre-operative
(c) and post-operative (d) chest
of a woman who had a breast
reconstruction with the MH
implant. Because of irradiation
on the right side, a muscular
cutaneous latissimus dorsi flap
was transposed
230 Eur J Plast Surg (2012) 35:229–233augmentation or reconstruction. The questionnaires were
filled out on average 3–3.5 years after the operation during
which the implant was inserted/replaced. Prior to the
replacement, women of the B groups had SG implants for
an average period of 13 years. The control group had hardly
any complaints, nor did the women of the C group. With
regard to their pre-operative health complaints, the women
of the B group improved on the whole spectrum, which was
statistically significant for most complaints. Importantly, the







































Fig. 2 Complaints reported by patients and controls. The frequency
of complaints (specified below the graphs) reported by the different
patient groups before (pre-op.) and after (post-op.) MH implant
insertion (C group) or replacement of their breast implants (B1 and B2
groups), and those reported by the Control group without implants is
illustrated by the graphs. The results were analysed by paired t tests:
ns not significant, * p<0.05; ** p<0.01; *** p<0.001














Control 34 35.0 n.a. n.a. n.a. n.a. 10 (29)
B1 22 50.5 15.5 yes 3 12 (55) 18 (82)
B2 13 47.5 10.5 no 3.5 5 (39) 10 (77)
C 42 36.0 0 n.a. 3 n.a. 6 (14)
n.a. not applicable
aPostoperative follow-up period
Eur J Plast Surg (2012) 35:229–233 231capsulectomy was also performed (Fig. 2). In both the B
and the C groups, the satisfaction of women with the MH
implant was high (Fig. 3).
Discussion
Working with the MH implant and keeping an eye on the
complaints that over the years have been mentioned by
w o m e nw i t ht h eS Gi m p l a n t[ 2–8], it became obvious that
there might be a novel disease that is probably caused by
silicone gel bleed [9–15]. The major difference between
the MH and SG implants is the content of the implant.
Both have a silicone elastomere shell, which is a solid
rubber. Since patients who start on the MH implant do not
develop the same complaints as some patients with the SG
implant, even after a longer follow-up period than was
used in this study for the B and the C groups (unpublished
results), it can be concluded that the silicone elastomere
shell does not seem to play a role in development of
complaints. Moreover, the replacement of the SG implant
by an MH implant resulted in a pronounced reduction of
complaints, which suggests a direct connection between
the contents of the SG implant and the complaints. This
connection is seen in the B group for ruptured as well as
intact SG implants (data not shown), indicating that
bleeding rather than rupture of the implants is associated
with the appearance of complaints. This is also in
concurrence with the finding that a capsulectomy (B1
group) resulted in a stronger reduction of complaints. The
explanation could be that the capsule is the first line of
defence of the body against gel bleed [11, 16]a n dw i l l
absorb the bleed until it can no longer be contained. If the
capsule is left in place during the replacement operation, it
will gradually regress, leaving the bled molecules behind
[2, 9, 12, 14, 15] and loosing the supreme moment to gain
clearance of much of the bleed in women with complaints.
Our data suggest that a simultaneous capsulectomy in
patients with complaints is preferred for an optimal
reduction of these complaints. However, in certain B
group patients, a number of complaints remained, even
after capsulectomy. It is possible that in these patients, a
certain threshold has been passed and that a chronic
disease has been generated that might have been triggered
by the exposure to silicones, but is not dependent on this
anymore. Indeed, symptoms of chronic autoimmune
diseases have been frequently reported in patients with
SG implants [4, 6, 8]. A larger retrospective study focused
on a comparison of the MH and SG implants has been
performed and is in preparation. The drawbacks of the MH
implant can be easily overcome. For instance, rippling in
case of a thin soft tissue cover can be corrected by
lipofilling or insertion of a Tissue Matrix. Surgeons tend to
be taken aback by the innocuous clear serous fluid in case
of rupture of the MH implant (Fig. 4), but one should keep
in mind that rupture of an SG implant goes unnoticed by
the patient and will lead to a highly increased exposure to
silicones, which may be detrimental to a women's health
[5]. Moreover, the insidious gel bleed of an intact SG
implant over the years can be catastrophic in some
women, who are genetically predisposed to the develop-
ment of chronic health complaints in relation to the SG






















Fig. 3 Patients' opinion on the
results of breast augmentation/
reconstruction with MH




indicated by the green bars,n o
change by the yellow bars and a
deterioration by the red bars.
The parameters evaluated as a
result of MH implantation
(C group) or SG implant
replacement with MH implants
(B1 and B2 groups) are specified
below the graph
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For women who do not wish to have an SG implant either
for augmentation or reconstruction, or who have developed
health complaints in relation to SG implants, or those who
do not want to have an extensive autologous breast
reconstruction with additional scarring, the MH implant
appears to be a good option. One should realise though that
it has to be replaced now and then because it is not
everlasting. But neither is the SG implant. Once a woman is
informed about the advantages and disadvantages of the
MH and SG implants, she can give a truly informed consent
about either implant and then she seems to be in favour of
the MH implant. Our study demonstrates that the vast
majority of individuals are satisfied with the MH implant.
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Fig. 4 Replacement of ruptured MH implant. A rupture of the MH
implant on the right side caused an enlargement of the breast within a
couple of days (a). The scar and capsule are incised under local
anaesthesia and the clear serous fluid is drained. The ruptured implant
is removed easily and the pocket is rinsed (b). A new MH implant is
inserted without drains, resulting in a normal breast size immediately
after the short procedure (c). Directly following this procedure, the
treated woman has to wear a supporting and compressive bra for a
period of 3 weeks
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